SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Advice from an Executive: How to Become a Leader in the Life Sciences
Eliseo Salinas, M.D., head of R&D for Delix Therapeutics offers his perspective on what it takes to become a leader in the life sciences and how to begin that transition.
October 7, 2022
 · 
5 min read
 · 
Gail Dutton
Evommune Team / Courtesy Evommune
Drug Development
Evommune’s Human Tissue-based Approach Enables Discovery and Development of Safer, Innovative Chronic Inflammation Therapies
Evommune’s novel human tissue-based assay system is proving to be a key differentiator as the company develops therapies to control chronic inflammation in autoimmune diseases.
October 7, 2022
 · 
7 min read
 · 
Gail Dutton
BlueSphere Bio CEO Keir Loiacono/courtesy of BlueS
Business
BlueSphere Bio’s Newly Minted CEO Calls for Urgency on Day One
With ambitions to enter the clinic in the first half of 2023, Keir Loiacono, esq., aims to double down on BlueSphere’s strengths rather than make any major course corrections.
October 4, 2022
 · 
4 min read
 · 
Gail Dutton
Synlogic CSO Dave Hava, Ph.D./courtesy Synlogic
Drug Development
Synlogic’s CSO Outlines Risks and Opportunities in Emerging Synthetic Biotics Space
Synlogic, Senti Biosciences and Novome are pioneering the field of synthetic biotics, which is so new there are only a handful of scientific articles using either that term or ‘engineered living therapeutics.
October 3, 2022
 · 
5 min read
 · 
Gail Dutton
Doug Edgeton_NCBC
Business
NC and Texas Biopharma Hubs Grow as Companies Look Beyond Boston & California
Biopharma companies are expanding beyond the traditional confines of Massachusetts and California with hubs forming – most notably – in the South and Southeast.
October 2, 2022
 · 
5 min read
 · 
Gail Dutton
All photos courtesy of Waters Corporation
Increasing Biologics Manufacturing Efficiency and Lowering Costs with QbD
Quality by design principles, when fully optimized, can decouple much of the process from the molecule itself, leading to significant efficiencies.
September 26, 2022
 · 
6 min read
 · 
Gail Dutton
Muhammad Al-Hajj_IO Biotech/Pete DeMuth_Elicio The
Drug Development
Cancer Vaccines Push Toward Viability with New Approaches and Targets
Advances in immuno-oncology and adaptive cell therapy that began about a decade ago are enabling fresh, biology-driven approaches to bring therapeutic cancer vaccines closer to fruition.
September 22, 2022
 · 
6 min read
 · 
Gail Dutton
Michelle Mellion, M.D./courtesy of PepGen
Business
PepGen’s Michelle Mellion is Redefining Success in Clinical Development
Beyond the usual challenge of delivering high-quality data that answers meaningful questions, PepGen’s Michelle Mellion is dedicated to “incorporating the patient’s voice into everything we do.”
September 20, 2022
 · 
5 min read
 · 
Gail Dutton
Mohammed Haneefa Nizamudeen_Getty Images
Drug Development
In Group of Firsts, ESMO Highlights Therapeutic Advances in Lung Cancer
NSCLC At ESMO: Pollution does indeed cause lung cancer; Tecentriq shows promise in poor prognosis patients, Amgen makes progress in KRAS G12-mutated disease and an update on a Daiichi Sankyo ADC.
September 14, 2022
 · 
6 min read
 · 
Gail Dutton
Leveraging Best-of-Breed Algorithms for Accuracy in Precision Medicine
There is no one-size-fits-all algorithm for AI that enables drug developers to quickly identify the features they seek. Instead, researchers are selecting best-of-breed algorithms for customized analytics.
September 13, 2022
 · 
5 min read
 · 
Gail Dutton
Maddie Meyer/Getty Images
Drug Development
Moderna’s Second Act: is the Momentum Sustainable?
Now that most people in North America and Europe are vaccinated and the COVID-19 pandemic is diminishing, Moderna is looking for its second act.
September 10, 2022
 · 
6 min read
 · 
Gail Dutton
Lance Minor_BDO, Milena Sullivan_Avalere
Policy
The Inflation Reduction Act’s Potential Impact on Research, Launch Strategy
Industry observers say the Inflation Reduction Act of 2022 could affect the direction of research, and some fear it may lead to further government forays into price control.
September 5, 2022
 · 
5 min read
 · 
Gail Dutton
Lance Minor_BDM, Kathryn McDonough_LinkedIn
Deals
Runway Extension Key to Survival as Biopharma Faces Hard Times Ahead
Hard times are forcing biopharma companies to extend their runways as they try to eke out every cent of value from their capital.
September 1, 2022
 · 
6 min read
 · 
Gail Dutton
Anne Elise Herold Li_Crowell & Moring, Amy Fix_Bar
Policy
Biopharma Needs to Protect more than Crown Jewel IP to Stay Competitive
The problem of intellectual property theft is greater than most biopharma executives realize, but the real issue is that companies are protecting only a fraction of their IP.
September 1, 2022
 · 
6 min read
 · 
Gail Dutton
Tips for Managing a Multigenerational, Post-Pandemic Workforce
While there has been a perception that young people are smarter or more creative, analyses from the Kellogg School of Management show most scientists make their breakthroughs later in life.
August 23, 2022
 · 
6 min read
 · 
Gail Dutton
Load More